# A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

> **NCT02087917** · PHASE2 · COMPLETED · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 376 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HS-25
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02087917
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2015-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02087917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02087917, "A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02087917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*